<DOC>
	<DOCNO>NCT02197078</DOCNO>
	<brief_summary>This protocol series comparative effectiveness safety analysis within periodically updated cohort patient initiate linagliptin , DPP-4 inhibitor , oral hypoglycemic medication , follow longitudinally occurrence variety health outcome . The primary analysis conduct among patient without prior within-class medication use .</brief_summary>
	<brief_title>Active Surveillance Research Program Assessment Safety Effectiveness Linagliptin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : A dispense oral hypoglycemic medication A diagnosis type 2 diabetes mellitus ( T2DM ) Exclusion criterion : less 18 year old miss ambiguous age sex information least one diagnosis type 1 diabetes mellitus le 6 month enrolment database precede date first dispense secondary diabetes history cancer endstage renal disease ( ESRD ) HIV organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>